Jan 26, 2024
Conversation about the global rise of obesity and its association with diabetes and the limited effectiveness of many pharmacotherapies tested for management of obesity. You will also learn about weight loss benefits, improvement in cardiovascular risk factors, and potential for cardiovascular event reduction with...
Jan 11, 2024
Conversation around current considerations for use of GLP-1 RAs in people with type 2 diabetes and chronic kidney disease (CKD). The discussion will include general considerations for management of diabetes in CKD, potential benefits of GLP-1 RA therapy in CKD (e.g., glycemic lowering, CV risk reduction, potential...